This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Posaconazole (NOXAFIL) spectrum of activity

Updated on 24/01/2019

ANTI-FUNGALS

Posaconazole (NOXAFIL) has broad spectrum coverage against invasive yeast and mould infections1-3

Spectrum of activity in vitro1-3

Correlation between in vitro activity and clinical efficacy is unknown

Organism1-3 Posaconazole (NOXAFIL)
MIC 90(μg/mL)
Amphotericin B
MIC 90(μg/mL)
Voriconazole
MIC 90(μg/mL)
Itraconazole
MIC 90(μg/mL)
Fluconazole
MIC 90(μg/mL)
Aspergillus spp. 0.5 1.0 0.5 2.0
Aspergillus flavus 0.5 2.0 1.0 1.0
Aspergillus fumigatus 0.5 1.0 0.5 1.0
Aspergillus nidulans 0.25 2.0* 0.5
Aspergillus niger 0.5 1.0 2.0 2.0
Aspergillus terreus 0.25 2.0 0.5 0.5
Candida albicans 0.063 1.0 0.063 0.25 2.0
Candida glabrata 2.0 1.0 2.0 4.0 64.0
Candida krusei 1.0 2.0 0.5 1.0 64.0
Coccidioides spp. 0.25 0.5 0.25 64.0
Cryptococcus spp.§ 0.25 1.0 0.125 0.5 8.0
Fusarium spp. 32.0 32.0 32.0 32.0^
Zygomycetes spp.** 4.0 2.0 128.0 32.0 >64.0
Mucor** 16.0 1.0 128.0 32.0
Rhizomucor** (0.016—0.25) (0.063—0.125) (2.0—16.0) (0.016—0.25)
Rhizopus** 8.0 2.0 128.0 32.0

Table adapted from Sabatelli F, et al. Antimicrob Agents Chemother 2006; Gonzalez GM, et al. J Clin Microbiol 2001; Sun QN, et al. Antimicrob Agents Chemother 2002.

* Please note for A. nidulans, Coccidioides and Zygomycetes spp., the susceptibility data were compiled from multiple sources. The remaining content was adapted from Sabatelli F et al. Antimicrob Agents Chemother. 2006;50:2009-2015

** The microbiological data suggest that posaconazole (NOXAFIL) is active against Rhizomucor, Mucor and Rhizopus, however the clinical data are currently too limited to assess the efficacy of posaconazole (NOXAFIL) against these causative agents.

Fewer than 10 strains tested.

C.immitis only.2

§Included strains of C.laurentii and C.neoformans.

IISpecies that causes chromoblastomycosis.

All species including F.solani.

^Fewer isolates (N = 23) were tested against itraconazole; therefore, the values for itraconazole cannot be compared directly.1

Related Content

 

References

  1. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important moulds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15.
  2. Gonzalez, G. M., R. Tijerina, L. K. Najvar, R. Bocanegra, M. Luther, M. G. Rinaldi, and J. R. Graybill. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. J. Clin. Microbiol. 2001;45:1854-1859
  3. Sun QN, Fothergill AW, McArthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2.

Supporting documentation

100 mg Tablets
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

300 mg IV
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

40 mg/ml Oral Suspension
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-POS-00009 | Date of Preparation: January 2019